Skip to main content
    A

    Arcadia Biosciences Inc (RKDA)

    Official site

    CONSUMER DEFENSIVE • PACKAGED FOODS • NASDAQ

    $0.19
    -0.00 (-2.01%)

    Market Cap: $1.32M

    Last updated: Nov 17, 2026 at 4:39 PM ET

    Arcadia Biosciences Inc (RKDA) Statistics

    Updated Nov 17, 2026. Figures from company filings and market prices; estimates from consensus analysts.

    Arcadia Biosciences (RKDA) has a market cap of $1.32M. Its share count is up 343.63% from a year earlier. It kept -202.09% of revenue as net income over the last 12 months.

    Total Valuation

    Market Cap$1.32M
    Latest price (Nov 17, 2026)$0.19

    Key Dates

    The next earnings report is expected on Mar 24, 2027, covering the quarter ending Dec 31, 2026.

    Next Earnings DateMar 24, 2027 (expected)
    Last Earnings DateNov 12, 2026
    Fiscal Year EndDecember

    Share Statistics

    The share count rose 102.68% in the quarter ended Sep 30, 2026 and grew 110.89% a year over 2 years.

    Shares Outstanding6.07M
    Shares Change (YoY)+343.63%
    Shares Change (QoQ)+102.68%
    Share Count Growth (2Y CAGR)+110.89%

    Valuation Ratios

    Sales and book value multiples are 0.2x and 0.5x. Its year-end P/S ranged from 0.6x to 13.5x from 2016 to 2025.

    P/S Ratio0.2x
    Forward P/S0.2x
    P/B Ratio0.5x
    P/TBV Ratio0.5x

    Valuation history and multiples

    Price Statistics

    The stock is down 94.97% over 52 weeks and trades 26.92% below its 50-day average.

    Beta (1Y)1.15
    52-Week Change-94.97%
    1-Month Change+30.83%
    3-Month Change-57.08%
    6-Month Change-79.36%
    5-Year Change-99.80%
    10-Year Change-99.99%
    Total Return (1Y)-94.97%
    Total Return (3Y CAGR)-60.20%
    Total Return (5Y CAGR)-69.08%
    Max Drawdown (1Y)-96.22%
    Max Drawdown (3Y)-97.73%
    Sharpe Ratio (1Y)-2.89
    Correlation with SPY (1Y)0.15
    50-Day Average$0.26
    200-Day Average$0.89
    52-Week Range$0.11 to $3.87
    RSI (14 Days)45.1
    Average Volume (20 Days)1.57M

    The 5 and 10 year changes compare month-end closes, adjusted for splits, through Oct 2026.

    Price chart

    Financial Position

    Current assets cover 3.58x current liabilities, and total debt is 0.00x shareholder equity.

    Current Ratio3.58x
    Quick Ratio2.82x
    Debt / Equity0.00x
    Interest Coverage-0.09x

    Returns and Efficiency

    Return on equity is -425.80% over the last 12 months, against a 5-year average of -80.93%.

    Return on Equity (ROE)-425.80%
    Return on Assets (ROA)-216.96%
    Return on Capital Employed (ROCE)-54.23%
    ROE (5Y Average)-80.93%
    ROA (5Y Average)-49.90%
    ROIC (5Y Average)-61.64%
    Asset Turnover0.76x
    Inventory Turnover3.13x
    Receivables Turnover8.55x
    Cash Conversion Cycle13 days

    Scores

    RKDA has an Altman Z-Score of -85.22, in the distress zone below 1.81, and a Piotroski F-Score of 2 of 9, in the weak band of 0 to 2.

    Altman Z-Score-85.22
    Altman Z ZoneDistress
    Piotroski F-Score2 of 9
    Piotroski StrengthWeak

    Income Statement

    Revenue of $5.06M over the last 12 months is down 2.11% from the 12 months before.

    Revenue$5.06M
    Revenue Growth (YoY)-2.11%
    Gross Profit$2.08M
    Operating Income-$3.49M
    Pretax Income-$7.26M
    Net Income-$10.23M
    EBITDA-$1.86M
    EBIT-$1.87M
    Reported EPS (TTM)-$3.17

    Trailing 12 months through Sep 30, 2026.

    Full financial statements

    Balance Sheet

    Shareholder equity funds 50.85% of the $4.72M in total assets.

    Cash and Equivalents$2.84M
    Total Debt$0
    Net Cash$2.84M
    Net Cash Per Share$0.47
    Working Capital$3.29M
    Shareholder Equity$2.40M
    Book Value Per Share$0.40
    Tangible Book Value$2.36M
    Tangible Book Per Share$0.39
    Total Assets$4.72M
    Total Liabilities$2.31M

    Balance sheet as of Sep 30, 2026.

    Full balance sheet

    Cash Flow

    Operating Cash Flow-$3.56M
    FCF Per Share-$1.48

    Trailing 12 months through Sep 30, 2026.

    Full cash flow statement

    Margins

    The operating margin is -68.95%.

    Gross Margin41.14%
    Operating Margin-68.95%
    Pretax Margin-143.49%
    Net Margin-202.09%
    EBITDA Margin-36.68%
    EBIT Margin-36.88%
    Gross Margin (5Y Average)23.60%

    Growth

    Revenue fell 13.16% a year over 3 years.

    Revenue Growth (3Y CAGR)-13.16%
    Revenue Growth (5Y CAGR)-9.57%
    Book Value Per Share Growth (2Y CAGR)-44.98%
    Tangible Book Per Share Growth (2Y CAGR)-45.16%

    Revenue and profit by year

    Dividends and Yields

    RKDA does not pay a dividend.

    Buyback Yield-347.65%
    Shareholder Yield-347.65%

    Stock Splits

    The last split was a 1-for-40 reverse split on Mar 1, 2023.

    Last Split DateMar 1, 2023
    Split TypeReverse split
    Split Ratio1:40

    Peer Position

    Against 5 similar companies, RKDA has the lowest P/S.

    P/S Ratio0.2x vs 1.3x median
    Revenue Growth (Trailing 4 Quarters, YoY)-2.11% vs +5.58% median

    Competitors compared

    Analyst Forecast

    Consensus estimates put revenue growth at 58.50% a year over the next fiscal year.

    Revenue Growth Forecast (1Y CAGR)+58.50%

    Price Target

    Analyst price targets are part of paid GNG plans. See plans

    GNG Valuation

    GNG viewUndervalued

    GNG fair value is part of GNG Pro. See plans

    Frequently Asked Questions About RKDA

    What is RKDA's market cap?

    Arcadia Biosciences has a market cap of $1.32M.

    How many shares of RKDA are outstanding?

    Arcadia Biosciences has 6.07M shares outstanding. The count is up 343.63% from a year earlier.

    Does RKDA pay a dividend?

    No. Arcadia Biosciences does not pay a dividend.

    How much debt does RKDA have?

    Arcadia Biosciences has $0 of total debt and $2.84M of cash and equivalents, a net cash position of $2.84M.